Recent 8-K filings for MDXG

• April 29, 2026, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 7.01item 9.01 ◈ Earnings Releases

  MiMedx Q1 net sales $59M (-33% YoY), loss $11M; cuts FY guidance to $260-290M

  Q1 net sales $59M, down 33% YoY from $88M; net loss $11M vs net income $7M a year ago.

• April 16, 2026, 7:59 PM ET other material materiality 0.80 negative item 5.02item 7.01item 9.01

  MiMedx Announces Restructuring and $40M Annual Cost Reduction Initiative

  Eliminated Chief Operating Officer position held by Ricci Whitlow; her departure effective immediately.

• February 25, 2026, 6:59 PM ET earnings materiality 0.85 neutral item 2.02item 7.01item 9.01

  MiMedx posts record Q4 sales $118M (+27% YoY); 2026 guidance $340-360M; $100M buyback

  Q4 net sales $118M, +27% YoY; full-year $419M, +20% YoY.

• January 12, 2026, 6:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  MiMedx updates investor presentation on January 12, 2026; no specific data available

  MiMedx updated its investor slide presentation on January 12, 2026.

• October 29, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  MiMedx Q3 record revenue $114M (+35% YoY); raises FY2025 guidance

  Q3 net sales $114M, up 35% YoY; GAAP net income $17M, diluted EPS $0.11.

• September 3, 2025, 7:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  MiMedx updates investor deck for Cantor conference; no specific new metrics revealed

  Company to participate in Cantor Global Healthcare Conference on September 3, 2025.

• July 30, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  MiMedX Q2 net sales $99M record, up 13% YoY; raises 2025 growth to low double-digits

  Net sales $99M (record), +13% YoY; GAAP net income $10M ($0.06 EPS); prior year included $9.3M settlement benefit.

• June 20, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  MiMedx shareholders re-elect nine directors and approve executive compensation at 2025 annual meeting

  Shareholders re-elected all nine director nominees including M. Kathleen Behrens, Joseph H. Capper, and William A. Hawkins.

• May 13, 2025, 7:59 PM ET other material materiality 0.25 neutral item 7.01item 9.01

  MiMedx updates investor presentation for BofA healthcare conference on May 13, 2025

  Company participated in BofA Securities 2025 Healthcare Conference on May 13, 2025.

• April 30, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  MiMedx Q1 net sales $88M (+4% YoY); GAAP EPS $0.05; reaffirms high single-digit growth outlook

  Net sales $88M (+4% YoY); GAAP net income $7M ($0.05 EPS); Adj. EBITDA $17M (20% margin).

• February 27, 2025, 6:59 PM ET other materiality 0.15 neutral item 7.01item 9.01

  MiMedx updates investor presentation; specific content not available in filing excerpt

  Investor presentation dated February 27, 2025, furnished under Regulation FD.

• February 26, 2025, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01

  MiMedx Q4 net sales $93M (+7% YoY), Adjusted EBITDA margin 21%, guides high-single-digit growth for 2025

  Q4 2024 net sales $93M (+7% YoY); full year $349M (+9% YoY). Adjusted EBITDA margin 21% for Q4.

• January 14, 2025, 6:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  MiMedx updates investor presentation; no material changes disclosed

  Investor presentation updated on January 14, 2025.

• December 16, 2024, 6:59 PM ET other material materiality 0.25 neutral item 1.01item 9.01

  MiMedx extends HQ lease through July 2029 and adopts director/officer indemnification agreements

  Lease with CPVF II West Oak LLC extended from July 31, 2026 to July 31, 2029; two optional two-year extensions added.

• November 18, 2024, 6:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  MiMedx Group presents at two investor conferences; slide deck furnished

  Senior management to present at Stifel 2024 Healthcare Conference on Nov 18 and Craig-Hallum Capital Group 15th Annual Alpha Select Conference on Nov 19.

• October 30, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01

  MiMedx Q3 net sales $84M (+3% YoY); raises FY2024 growth outlook to high single-digits

  GAAP net income $8.1M ($0.05 EPS); Adjusted EBITDA $18.2M (21.6% margin), up from $17.6M a year ago.

• July 31, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 9.01

  MiMedx Q2 revenue $87M (+7% YoY), GAAP EPS $0.12, Adjusted EBITDA margin 23%

  Net sales $87M, up 7% YoY; GAAP net income $18M, EPS $0.12.

• June 7, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  MiMedx shareholders re-elect all nine directors, approve say-on-pay at AGM

  80.74% of shares represented; all nine director nominees re-elected with substantial votes for (over 88M each).

• April 30, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  MiMedx Q1 net sales $85M (+18% YoY); GAAP net income $9M; Adj. EBITDA $19M (22% margin)

  Net sales $85M, up 18% YoY; gross margin improved to 84.7% from 82.7%.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

5 positive 2 negative 12 neutral

source · MDXG on sec.gov